Department of Medical Oncology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500HB Nijmegen, The Netherlands.
Nat Rev Drug Discov. 2011 Aug 1;10(8):591-600. doi: 10.1038/nrd3500.
Our insight into antitumour immune responses has increased considerably during the past decades, yet the development of immunotherapy as a treatment modality for cancer has been hampered by several factors. These include difficulties in the selection of the optimal dose and schedule, the methods of evaluation, and financial support. Although durable clinical remissions have been observed with various immunotherapeutic strategies, the percentage of patients who benefited from these interventions has remained too small to justify the general use of such strategies. However, the recent positive results of clinical trials with novel immunoactive drugs as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy may herald a new era for the immunotherapy of cancer.
在过去的几十年中，我们对抗肿瘤免疫反应的认识有了很大的提高，但是免疫疗法作为癌症的治疗方式的发展受到了几个因素的阻碍。这些因素包括最佳剂量和方案的选择、评估方法和资金支持方面的困难。尽管各种免疫治疗策略观察到了持久的临床缓解，但受益于这些干预措施的患者比例仍然太小，无法证明这些策略的普遍应用是合理的。然而，新型免疫活性药物的临床试验的最近积极结果以及免疫疗法与化疗之间的意外正相互作用的发现，可能为癌症的免疫治疗带来一个新时代。
